Drug Profile


Alternative Names: AMG-162; PRALIA; Prolia; Ranmark; Xgeva

Latest Information Update: 22 Jul 2017

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; Daiichi Sankyo Company; European Thoracic Oncology Platform; GlaxoSmithKline
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant hypercalcaemia; Bone cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bone cancer; Bone disorders; Bone metastases; Male osteoporosis; Malignant hypercalcaemia; Osteoporosis; Postmenopausal osteoporosis; Rheumatoid arthritis
  • Phase III Breast cancer; Corticosteroid-induced osteoporosis; Non-small cell lung cancer; Osteogenesis imperfecta
  • No development reported Multiple myeloma

Most Recent Events

  • 03 Jul 2017 Launched for Rheumatoid arthritis in Japan (SC)
  • 29 Jun 2017 Amgen completes the phase III GIOP trial for Corticosteroid-induced osteoporosis in USA, Canada, Argentina, Colombia, Mexico, Belgium, Czech Republic, Denmark, France, Germany, Hungary, Netherlands, Poland, Spain, Russia and South Korea (SC) (NCT01575873)
  • 19 Jun 2017 Launched for Bone cancer (In adolescents) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top